← Statins × all-cause mortality

TrialPharmacogenetics and genomics2009

The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.

Anke-Hilse Maitland-van der Zee et al.PubMed ↗Full text ↗Publisher ↗

  • Pravastatinlooks bad hereHigher combined CHD, no clear link with combined CHD.Correlation only, not a test of it.

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Pravastatin went with higher combined CHD

+33%+1% to +76%

pravastatin vs usual care, in F5 Arg506Gln G>A (rs6025) polymorphism

Bigger than 7 in 10 for all-cause mortality

As reported

HR 1.33, 95% CI 1.01–1.76

Correlation · may be no link

No clear link with combined CHD

1.9×1× to 3.6×

pravastatin vs usual care, in F7 Arg353Gln G>A (rs6046) polymorphism

Bigger than 9 in 10 for all-cause mortality

As reported

HR 1.92, 95% CI 1.00–3.65

Who was studied, and how

9,624people with cardiovascular disease, in this paper

Already taking pravastatin, or nottheir own situation, not assigned

on pravastatin
usual care

Pravastatin went with higher combined CHD+33%

correlation, not a test

the abstract, start to end

… combined CHD [interaction hazard ratio = 1.33, 95% confidence interval (1.01-1.76) and interaction hazard ratio = 1.92, 95% confidence interval …

← favours treatmentfavours comparator →
could be chance
Combined CHDpravastatin vs usual care, in F5 Arg506Gln G>A (rs6025) polymorphism
HR 1.331.01–1.76
Combined CHDpravastatin vs usual care, in F7 Arg353Gln G>A (rs6046) polymorphism
HR 1.921.00–3.65
StatinsAll-cause mortality
1 / 4

4 papers cite it

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 19415820